文献速递妇科肿瘤

引入淋巴结清扫术和定制放疗后非子宫内膜样子宫内膜癌生存率提高——一项基于人群的队列研究

Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study.
PubMed 文献 · Eur J Cancer · 2022-04-29

该研究基于瑞典妇科癌症质量登记处,纳入2010至2017年228例早期非子宫内膜样子宫内膜癌患者,评估首个国家指南(NGEC)实施前后生存变化。NGEC实施后5年总生存率72.0% vs 实施前57.3%(log-rank p=0.018),无病生存率70.1% vs 52.1%(log-rank p=0.008),辅助放疗使用从92.7%降至42.4%(p<0.001)。

要点

  • NGEC实施后5年总生存率72.0% vs 实施前57.3%(log-rank p=0.018)。
  • NGEC实施后5年无病生存率70.1% vs 实施前52.1%(log-rank p=0.008)。
  • 辅助放疗使用从实施前92.7%降至实施后42.4%(p<0.001)。

核心结论

  • 在术前早期非子宫内膜样子宫内膜癌人群中,引入淋巴结分期以定制辅助治疗并减少盆腔放疗后,生存率显著改善。

研究设计与样本

  • 基于人群的队列研究,使用瑞典妇科癌症质量登记处识别2010至2017年所有早期非子宫内膜样子宫内膜癌女性。

主要发现

  • 共纳入228例患者,67例(29%)在5年内复发。
  • 复发组总生存率13.4%(95%CI:7.3-24.7)vs 无复发组88.5%(95%CI:83.4-93.9)(log-rank p<0.001)。
  • 全队列无病生存率61.9%(95%CI:55.7-68.7)。
  • NGEC实施前总生存率57.3%(95%CI:48.2-68.1)、无病生存率52.1%(95%CI:43.0-63.1),实施后总生存率72.0%(95%CI:64.2-80.7;log-rank p=0.018)、无病生存率70.1%(95%CI:62.4-78.7;log-rank p=0.008)。
  • 多变量回归分析中,年龄、FIGO分期和淋巴结清扫为显著预后因素,行淋巴结清扫降低复发或死亡风险,HR 0.58(95%CI:0.33-1.00)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate recurrence and survival in non-endometrioid endometrial cancer in a population-based cohort and evaluate the implementation of the first national guidelines (NGEC) recommending pelvic and paraaortic lymphadenectomy for surgical staging and tailored adjuvant therapy. METHODS: A population-based cohort study that used the Swedish quality registry for gynaecological cancer for the identification of all women with early-stage non-endometrioid endometrial cancer between 2010 and 2017. Five-year overall (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method. The Cox proportional hazards regression model was used to evaluate the effect of age, FIGO stage, primary treatment and lymph node dissection on DFS. RESULTS: There were 228 patients included in the study cohort and 67 (29%) patients had a recurrence within five years. In the recurrence cohort, the OS was 13.4% (95%CI:7.3-24.7) compared to 88.5% (95%CI:83.4-93.9) if no recurrence occurred (log-rank p < 0.001). The DFS for the complete cohort was 61.9% (95%CI:55.7-68.7). The OS before implementation of NGEC was 57.3% (95%CI:48.2-68.1) and the DFS was 52.1% (95%CI:43.0-63.1) compared to an OS of 72.0% (95%CI:64.2-80.7; log-rank p = 0.018) and a DFS of 70.1% (95%CI:62.4-78.7; log-rank p = 0.008) after implementing NGEC. Patients received adjuvant radiotherapy in 92.7% before and 42.4% after NGEC implementation (p < 0.001). In the multivariable regression analysis, age, FIGO stage and lymph node dissection were found to be significant prognostic factors, where having a lymph node dissection decreased the risk of recurrence or death with a HR of 0.58 (95%CI:0.33-1.00). CONCLUSION: In this population-based cohort of preoperative early-stage non-endometrioid EC, a significant improvement in survival was seen after NGEC implementation where lymph node staging for tailoring adjuvant therapy was introduced and less pelvic radiotherapy was given.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Åkesson Å, Adok C, Dahm-Kähler P, et al. Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study. Eur J Cancer. 2022. PMID: 35500461. doi:10.1016/j.ejca.2022.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。